VSHP Region 1 Virtual Meeting

OBIZUR®: A FIRST-LINE TREATMENT OPTION FOR ACQUIRED HEMOPHILIA A

Program Objectives

• Review the clinical features, diagnosis, and management of acquired hemophilia A (AHA) Share the clinical study data (efficacy and safety) supporting the indication of OBIZUR for treatment of bleeding episodes in adults with AHA Discuss patient cases in which OBIZUR may be an appropriate treatment option

There will not be CE or meal associated with this meeting.  

Registration flyer is attached.